Changing the Face of Cardiovascular Trial Participation: Moving Beyond Middle-Aged White Guys by David D. Waters, MD

Get full text

Atorvastatin Has a Dose‐Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double‐Blind Randomized Controlled Trials by Liffert Vogt, Sripal Bangalore, Rana Fayyad, Shari Melamed, G. Kees Hovingh, David A. DeMicco, David D. Waters

Get full text

The association between lipid levels and leukocyte count: A cross-sectional and longitudinal analysis of three large cohorts by Sonia Sawant, Bradley Tucker, Praween Senanayake, David D. Waters, Sanjay Patel, Kerry-Anne Rye, Kwok Leung Ong, Blake J. Cochran

Get full text

Relationship of High‐Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin by Kwok Leung Ong, David D. Waters, Rana Fayyad, Liffert Vogt, Shari Melamed, David A. DeMicco, Kerry‐Anne Rye, Philip J. Barter

Get full text

Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers. by Benoit J Arsenault, Philip Barter, David A DeMicco, Weihang Bao, Gregory M Preston, John C LaRosa, Scott M Grundy, Prakash Deedwania, Heiner Greten, Nanette K Wenger, James Shepherd, David D Waters, John J P Kastelein, Treating to New Targets (TNT) Investigators

Get full text